[Effects of influenza vaccination on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study].
Identifieur interne : 000501 ( Main/Exploration ); précédent : 000500; suivant : 000502[Effects of influenza vaccination on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study].
Auteurs : Leslie Barrionuevo Rosas [Espagne] ; Cristina Masuet Aumatell ; Josep M. Ramon TorrellSource :
- Gaceta sanitaria [ 1578-1283 ]
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Agents antiVIH (usage thérapeutique), Charge virale (MeSH), Espagne (épidémiologie), Femelle (MeSH), Humains (MeSH), Hôpitaux universitaires (MeSH), Infections à VIH (immunologie), Infections à VIH (sang), Infections à VIH (traitement médicamenteux), Infections à VIH (épidémiologie), Mâle (MeSH), Numération des lymphocytes CD4 (MeSH), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (MeSH), VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (MeSH), Vaccination (MeSH), Vaccins antigrippaux (pharmacologie), Études de cohortes (MeSH), Études rétrospectives (MeSH).
- MESH :
- immunologie : Infections à VIH.
- pharmacologie : Vaccins antigrippaux.
- sang : Infections à VIH.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- épidémiologie : Espagne, Infections à VIH.
- Adulte, Adulte d'âge moyen, Charge virale, Femelle, Humains, Hôpitaux universitaires, Mâle, Numération des lymphocytes CD4, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), VIH-2 (Virus de l'Immunodéficience Humaine de type 2), Vaccination, Études de cohortes, Études rétrospectives.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adult (MeSH), Anti-HIV Agents (therapeutic use), CD4 Lymphocyte Count (MeSH), Cohort Studies (MeSH), Female (MeSH), HIV Infections (blood), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV Infections (immunology), HIV-1 (MeSH), HIV-2 (MeSH), Hospitals, University (MeSH), Humans (MeSH), Influenza Vaccines (pharmacology), Male (MeSH), Middle Aged (MeSH), Retrospective Studies (MeSH), Spain (epidemiology), Vaccination (MeSH), Viral Load (MeSH).
- MESH :
- chemical , pharmacology : Influenza Vaccines.
- chemical , therapeutic use : Anti-HIV Agents.
- geographic , epidemiology : Spain.
- blood : HIV Infections.
- drug therapy : HIV Infections.
- epidemiology : HIV Infections.
- immunology : HIV Infections.
- Adult, CD4 Lymphocyte Count, Cohort Studies, Female, HIV-1, HIV-2, Hospitals, University, Humans, Male, Middle Aged, Retrospective Studies, Vaccination, Viral Load.
Abstract
OBJECTIVE
To determine the incidence of immunologic change in the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients in the first quarter after influenza vaccination (P-CIR) and to compare the demographic and clinical characteristics associated with this change.
METHODS
We studied 105 patients with HIV/AIDS in a retrospective hospital cohort between 2001-2006. P-CIR was considered as a decrease of >3% in the prevaccination CD4+ percentage. Crude and adjusted OR (sex, age, antiretroviral therapy, clinical stability, prevaccination viremia and prevaccination total CD4) were evaluated by logistic regression (95%CI).
RESULTS
The incidence of P-CIR was 33.3%. P-CIR was persistent in 31.4% for 7 months after vaccination regardless of high prevaccination viremia. No association was found between demographic and clinical variables and P-CIR [crude OR: 0.90 (0.17-4.8); adjusted OR: 1.09 (0.17-6.8)].
CONCLUSIONS
The results showed that the immunological change after vaccination was not inconsiderable. However, this change was mainly transient.
DOI: 10.1016/j.gaceta.2008.10.011
PubMed: 19286280
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Effects of influenza vaccination on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study].</title><author><name sortKey="Barrionuevo Rosas, Leslie" sort="Barrionuevo Rosas, Leslie" uniqKey="Barrionuevo Rosas L" first="Leslie" last="Barrionuevo Rosas">Leslie Barrionuevo Rosas</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Masuet Aumatell, Cristina" sort="Masuet Aumatell, Cristina" uniqKey="Masuet Aumatell C" first="Cristina" last="Masuet Aumatell">Cristina Masuet Aumatell</name></author><author><name sortKey="Ramon Torrell, Josep M" sort="Ramon Torrell, Josep M" uniqKey="Ramon Torrell J" first="Josep M" last="Ramon Torrell">Josep M. Ramon Torrell</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009 Jul-Aug</date><idno type="RBID">pubmed:19286280</idno><idno type="pmid">19286280</idno><idno type="doi">10.1016/j.gaceta.2008.10.011</idno><idno type="wicri:Area/Main/Corpus">00527</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00527</idno><idno type="wicri:Area/Main/Curation">000527</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000527</idno><idno type="wicri:Area/Main/Exploration">000527</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Effects of influenza vaccination on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study].</title><author><name sortKey="Barrionuevo Rosas, Leslie" sort="Barrionuevo Rosas, Leslie" uniqKey="Barrionuevo Rosas L" first="Leslie" last="Barrionuevo Rosas">Leslie Barrionuevo Rosas</name><affiliation wicri:level="3"><nlm:affiliation>Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Masuet Aumatell, Cristina" sort="Masuet Aumatell, Cristina" uniqKey="Masuet Aumatell C" first="Cristina" last="Masuet Aumatell">Cristina Masuet Aumatell</name></author><author><name sortKey="Ramon Torrell, Josep M" sort="Ramon Torrell, Josep M" uniqKey="Ramon Torrell J" first="Josep M" last="Ramon Torrell">Josep M. Ramon Torrell</name></author></analytic><series><title level="j">Gaceta sanitaria</title><idno type="eISSN">1578-1283</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Anti-HIV Agents (therapeutic use)</term><term>CD4 Lymphocyte Count (MeSH)</term><term>Cohort Studies (MeSH)</term><term>Female (MeSH)</term><term>HIV Infections (blood)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (immunology)</term><term>HIV-1 (MeSH)</term><term>HIV-2 (MeSH)</term><term>Hospitals, University (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (pharmacology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Spain (epidemiology)</term><term>Vaccination (MeSH)</term><term>Viral Load (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Charge virale (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hôpitaux universitaires (MeSH)</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (sang)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (épidémiologie)</term><term>Mâle (MeSH)</term><term>Numération des lymphocytes CD4 (MeSH)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (MeSH)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (MeSH)</term><term>Vaccination (MeSH)</term><term>Vaccins antigrippaux (pharmacologie)</term><term>Études de cohortes (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Cohort Studies</term><term>Female</term><term>HIV-1</term><term>HIV-2</term><term>Hospitals, University</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Vaccination</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Charge virale</term><term>Femelle</term><term>Humains</term><term>Hôpitaux universitaires</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term><term>Vaccination</term><term>Études de cohortes</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To determine the incidence of immunologic change in the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients in the first quarter after influenza vaccination (P-CIR) and to compare the demographic and clinical characteristics associated with this change.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We studied 105 patients with HIV/AIDS in a retrospective hospital cohort between 2001-2006. P-CIR was considered as a decrease of >3% in the prevaccination CD4+ percentage. Crude and adjusted OR (sex, age, antiretroviral therapy, clinical stability, prevaccination viremia and prevaccination total CD4) were evaluated by logistic regression (95%CI).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The incidence of P-CIR was 33.3%. P-CIR was persistent in 31.4% for 7 months after vaccination regardless of high prevaccination viremia. No association was found between demographic and clinical variables and P-CIR [crude OR: 0.90 (0.17-4.8); adjusted OR: 1.09 (0.17-6.8)].</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The results showed that the immunological change after vaccination was not inconsiderable. However, this change was mainly transient.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19286280</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1283</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><MedlineDate>2009 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Gaceta sanitaria</Title><ISOAbbreviation>Gac Sanit</ISOAbbreviation></Journal><ArticleTitle>[Effects of influenza vaccination on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study].</ArticleTitle><Pagination><MedlinePgn>315-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gaceta.2008.10.011</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the incidence of immunologic change in the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients in the first quarter after influenza vaccination (P-CIR) and to compare the demographic and clinical characteristics associated with this change.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied 105 patients with HIV/AIDS in a retrospective hospital cohort between 2001-2006. P-CIR was considered as a decrease of >3% in the prevaccination CD4+ percentage. Crude and adjusted OR (sex, age, antiretroviral therapy, clinical stability, prevaccination viremia and prevaccination total CD4) were evaluated by logistic regression (95%CI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of P-CIR was 33.3%. P-CIR was persistent in 31.4% for 7 months after vaccination regardless of high prevaccination viremia. No association was found between demographic and clinical variables and P-CIR [crude OR: 0.90 (0.17-4.8); adjusted OR: 1.09 (0.17-6.8)].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results showed that the immunological change after vaccination was not inconsiderable. However, this change was mainly transient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barrionuevo Rosas</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masuet Aumatell</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ramon Torrell</LastName><ForeName>Josep M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Efectos de la vacunación antigripal sobre el porcentaje de linfocitos T CD4 positivos en pacientes VIH 1/2 positivos: estudio de una cohorte.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gac Sanit</MedlineTA><NlmUniqueID>8901623</NlmUniqueID><ISSNLinking>0213-9111</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="Y">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015498" MajorTopicYN="Y">HIV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006785" MajorTopicYN="N">Hospitals, University</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>05</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19286280</ArticleId><ArticleId IdType="pii">S0213-9111(09)00093-4</ArticleId><ArticleId IdType="doi">10.1016/j.gaceta.2008.10.011</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><noCountry><name sortKey="Masuet Aumatell, Cristina" sort="Masuet Aumatell, Cristina" uniqKey="Masuet Aumatell C" first="Cristina" last="Masuet Aumatell">Cristina Masuet Aumatell</name><name sortKey="Ramon Torrell, Josep M" sort="Ramon Torrell, Josep M" uniqKey="Ramon Torrell J" first="Josep M" last="Ramon Torrell">Josep M. Ramon Torrell</name></noCountry><country name="Espagne"><region name="Catalogne"><name sortKey="Barrionuevo Rosas, Leslie" sort="Barrionuevo Rosas, Leslie" uniqKey="Barrionuevo Rosas L" first="Leslie" last="Barrionuevo Rosas">Leslie Barrionuevo Rosas</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000501 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000501 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19286280
|texte= [Effects of influenza vaccination on the percentage of CD4+ T lymphocytes in HIV 1/2 positive patients: a cohort study].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19286280" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |